stockrowLatest quarter
ResMed reported Q4 FY2026 revenue of $1.5 billion, compared with $1.3 billion a year earlier, a change of 8.58%. The company’s revenue, as the consensus counts it, was $1.5 billion against consensus revenue of $1.5 billion, exceeding the consensus by 0.17%.
ResMed reported adjusted EPS, as the consensus counts it, of $2.95 for the quarter to June 30, 2026, above consensus adjusted EPS of $2.90 by 1.72%. The company reported diluted EPS of $2.64 in Q4 FY2026, compared with $2.58 in Q4 FY2025, a change of 2.33%.
ResMed reported gross margin of 58.8%, compared with 60.8% a year earlier, a change of −2.0 percentage points. The company reported operating margin of 30.7%, compared with 33.7% in Q4 FY2025, a change of −3.1 percentage points. ResMed reported free cash flow of $397.4 million, compared with $505.0 million a year earlier, a change of −21.3%.
| Q4 FY2026 | Q4 FY2025 | Change | |
|---|---|---|---|
| Revenue | $1.5 billion | $1.3 billion | 8.58% |
| Diluted EPS | $2.64 | $2.58 | 2.33% |
| Gross margin | 58.8% | 60.8% | −2.0 percentage points |
| Operating margin | 30.7% | 33.7% | −3.1 percentage points |
| Free cash flow | $397.4 million | $505.0 million | −21.3% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $2.95 | $2.90 | Beat by 1.72% |
| Revenue | $1.5 billion | $1.5 billion | In line |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
ResMed did not provide an earnings-call transcript or other latest-call commentary for this page.
The company’s filing discusses fiscal-year results and does not provide management’s latest-call comments on demand, pricing, margins, investment, competition, the quarter ahead, or analyst questions.
Guidance
ResMed did not provide management guidance for this page. The company therefore did not state any changed outlook, discontinued outlook metric, or other updated guidance for investors to compare with a previous guide.